Ascendis Pharma ADR had its Relative Strength (RS) Rating upgraded from 85 to 91 Tuesday.
Here Are 3 Keys For Successful Stock Investing
This unique rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History shows that the best stocks typically have an 80 or higher RS Rating as they launch their biggest climbs.
Ascendis Pharma ADR is now considered extended and out of buy range after clearing a 161.00 buy point in a second-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company reported 0% earnings growth last quarter, while sales growth came in at 6%.
The company holds the No. 65 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
